



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on December 6, 2005

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group 1636

Patent Application

Docket No. USF-T144XCZ1

Serial No. 10/759,328

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maria Marvich, Ph.D.  
Art Unit : 1636  
Applicant : Said M. Sebti  
Serial No. : 10/759,328  
Filed : January 16, 2004  
Conf. No. : 8343  
For : RhoB as a Suppressor of Cancer Cell Growth, Cell Transformation, and Metastasis

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicant has not submitted copies of the published U.S. applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

Included with this supplemental Information Disclosure Statement is a copy of an Office

Action issued in a related application, U.S. serial no. 10/049,502, filed February 15, 2002. As the

12/13/2005 SSITHIB1 00000033 190065 10759328

02 FC:1806

180.00 DA

J:\USF\T144XCZ1\PTO\SIDS1.pto.doc/DNB/mv

file wrapper of this related application is available to the Examiner, unless requested by the Examiner, the applicant will not be submitting subsequent Office Actions from this related application.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/759,328
Filing Date	January 16, 2004
First Named Inventor	Said M. Sebti
Art Unit	1636
Examiner Name	Maria Marvich, Ph.D.
Attorney Docket Number	USF-T144XCZ1

Sheet

1

of

2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2003-0018003 A1	01-23-2003	Sebti	All
	U2	US-2002-0034725 A1	03-21-2002	McKenna et al.	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/759,328
Filing Date	January 16, 2004
First Named Inventor	Said M. Sebti
Group Art Unit	1636
Examiner Name	Maria Marvich, Ph.D.
Attorney Docket Number	USF-T144XCZ1

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ADJEI, A.A. "Ras signaling pathway proteins as therapeutic targets" <i>Curr Pharm Design</i> , 2001, 7:1581-1594.	
	R2	CAPONIGRO, F. "Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy?" <i>Anti-Cancer Drugs</i> , 2002, 13:891-897.	
	R3	END, D.W. <i>et al.</i> "Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 <i>in vivo</i> and <i>in vitro</i> " <i>Cancer Res.</i> , 2001, 61:131-137.	
	R4	GURA, T. "Systems for identifying new drugs are often faulty" <i>Science</i> , 1997, 278:1041-1042.	
	R5	KERBEL, R.S. "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans" <i>Cancer Biol. &amp; Ther.</i> , 2003, 2(4 Supp. 1):S134-S139.	
	R6	REUTER, C.W. <i>et al.</i> "Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?" <i>Blood</i> , 2000, 96:1655-1669.	
	R7	ROBSON, T. and HIRST, D. "Transcriptional targeting in cancer gene therapy" <i>J. Biomed. Biotech.</i> , 2003, 2:110-137.	
	R8	SHI, B. <i>et al.</i> "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes <i>in vitro</i> and enhances their antitumor activity <i>in vivo</i> " <i>Cancer. Chemother. Pharmacol.</i> , 2000, 46:387-393.	
	R9	VOSKOGLU-NOMIKOS, T. <i>et al.</i> "Clinical predictive value of the <i>in vitro</i> cell line, human xenograft, and mouse allograft preclinical cancer models" <i>Clin. Cancer Res.</i> , 2003, 9:4227-4239.	
	R10	Office Action mailed 06/28/2005 in U.S. Serial No. 10/049,502, filed February 15, 2002.	
	R		
	R		
	R		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.